Algorae Pharmaceuticals (ASX:1AI) has signed an exclusive commercial and licensing agreement with Zydus Lifesciences to introduce a portfolio of ten products into Australia and New Zealand.
The arrangement will target hospital and community care channels and covers injectable, oral and specialty pharmaceutical products that are expected to be commercialised through Algorae’s ANZ platform, subject to Therapeutic Goods Administration and other regulatory approvals.
Algorae said the collaboration establishes a framework for joint prioritisation of products based on regulatory pathways, supply readiness and market access considerations. The parties completed customary commercial and technical due diligence and confirmed alignment with applicable Australian and New Zealand regulatory and market requirements.
Algorae Chief Commercial Officer Mr Vishal Shah described the deal as closely aligned with the company’s commercial plan. "The product-specific exclusive agreement with Zydus covers a broad range of injectable, oral and specialty medicines, and supports our strategy to build a reliable, compliant portfolio for the ANZ market. The collaboration brings together complementary capabilities to support long-term portfolio development."
Algorae Chairman Mr David Hainsworth said the partnership advances the company’s long-term goals. "This agreement strengthens Algorae’s commercial platform and supports long-term portfolio development in highly regulated markets. We welcome the collaboration with Zydus and the opportunities it presents for sustainable growth."
Zydus Lifesciences is a global pharmaceutical company headquartered in Ahmedabad, India, with manufacturing and development capabilities across sterile injectables, oral dosage forms, specialty formulations, and complex generics. The company operates more than 20 manufacturing facilities in India, the United States, and Brazil, and supplies medicines to regulated and emerging markets worldwide.